Pancreatic ductal adenocarcinoma (PDA) is a lethal cancer resistant to immunotherapy. We create a PDA mouse model and show that neoantigen expression is required for intratumoral T cell accumulation and response to immune checkpoint blockade. By generating a peptide:MHC tetramer, we identify that PDA induces rapid intratumoral, and progressive systemic, tumor-specific T cell exhaustion. Monotherapy PD-1 or PD-L1 blockade enhances systemic T cell expansion and induces objective responses that require systemic T cells. However, tumor escape variants defective in IFNγ-inducible Tap1 and MHC class I cell surface expression ultimately emerge. Combination PD-1 + PD-L1 blockade synergizes therapeutically by increasing intratumoral KLRG1+Lag3−TNFα+ tumor-specific T cells and generating memory T cells capable of expanding to spontaneous tumor recurrence, thereby prolonging animal survival. Our studies support that PD-1 and PD-L1 are relevant immune checkpoints in PDA and identify a combination for clinical testing in those patients with neoantigen-specific T cells.

Learn more:

Foxp3 / Transcription Factor Staining Buffer Kit was used for nuclear labelling before subjecting the cells to flow cytometry analysis. Cells were stained with Ghost Violet™ 510 Viability Dye and Ghost Dye™ Red 780 for dead cell exclusion.

Learn more about our Foxp3 / Transcription Factor Staining Buffer Kit. View our full selection of Ghost Viability Dyes™ and  flow cytometry antibodies. 



Tags: DMEM High Glucose Media